Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

115 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Tamoxifen vs Tamoxifen plus 13-cis-retinoic acid vs Tamoxifen plus Interferon alpha-2a as first-line endocrine treatments in advanced breast cancer: updated results of a phase II, prospective, randomised multicentre trial.
Chiesa MD, Passalacqua R, Michiara M, Franciosi V, Di Costanzo F, Bisagni G, Camisa R, Buti S, Tomasello G, Cocconi G; Italian Oncology Group for Clinical Research. Chiesa MD, et al. Among authors: bisagni g. Acta Biomed. 2007 Dec;78(3):204-9. Acta Biomed. 2007. PMID: 18330080 Clinical Trial.
A Prognostic Model Based on Residual Cancer Burden and Tumor-Infiltrating Lymphocytes on Residual Disease after Neoadjuvant Therapy in HER2+ Breast Cancer.
Miglietta F, Ragazzi M, Fernandes B, Griguolo G, Massa D, Girardi F, Bottosso M, Bisagni A, Zarrilli G, Porra F, Iannaccone D, Dore L, Gaudio M, Santandrea G, Fassan M, Lo Mele M, De Sanctis R, Zambelli A, Bisagni G, Guarneri V, Dieci MV. Miglietta F, et al. Among authors: bisagni a, bisagni g. Clin Cancer Res. 2023 Sep 1;29(17):3429-3437. doi: 10.1158/1078-0432.CCR-23-0480. Clin Cancer Res. 2023. PMID: 37417941 Free PMC article.
Low-dose aminoglutethimide with and without hydrocortisone replacement as a first-line endocrine treatment in advanced breast cancer: a prospective randomized trial of the Italian Oncology Group for Clinical Research.
Cocconi G, Bisagni G, Ceci G, Bacchi M, Boni C, Brugia M, Carpi A, Di Costanzo F, Franciosi V, Gori S, et al. Cocconi G, et al. Among authors: bisagni g. J Clin Oncol. 1992 Jun;10(6):984-9. doi: 10.1200/JCO.1992.10.6.984. J Clin Oncol. 1992. PMID: 1588379 Clinical Trial.
Cisplatin and etoposide in advanced colorectal carcinoma.
Passalacqua R, Bisagni G, Cocconi G, Boni C, Di Blasio B, Ceci G. Passalacqua R, et al. Among authors: bisagni g. Ann Oncol. 1991 Oct;2(9):687-8. doi: 10.1093/oxfordjournals.annonc.a058050. Ann Oncol. 1991. PMID: 1742225 Free article.
A comparison of continuation versus late intensification followed by discontinuation of chemotherapy in advanced breast cancer. A prospective randomized trial of the Italian Oncology Group for Clinical Research (G.O.I.R.C.).
Cocconi G, Bisagni G, Bacchi M, Buzzi F, Canaletti R, Carpi A, Ceci G, Colozza A, De Lisi V, Lottici R, et al. Cocconi G, et al. Among authors: bisagni g. Ann Oncol. 1990;1(1):36-44. doi: 10.1093/oxfordjournals.annonc.a057671. Ann Oncol. 1990. PMID: 2078484 Free article. Clinical Trial.
115 results